Acquired immune deficiency syndrome (AIDS)
AIDS-related complex (ARC)
interleukin-2, therapy trial
Springer Online Journal Archives 1860-2000
Abstract In the context of a clinical phase I/II therapy study with recombinant interleukin-2 (rIL-2), we monitored immunological alterations in four patients with acquired immune deficiency syndrome (AIDS) and three patients with AIDS-related complex (ARC). By determining the surface phenotypes andin vitro functions of peripheral blood mononuclear cells (PBMC) before, during, and after treatment with rIL-2, we observed transient changes in all important leukocyte subpopulations, a minor restoration of immune reactivityin vitro, and an improvement in skin reactivityin vivo. In particular, we found (i) a transient increase in C3b receptor-mediated monocyte activation in ARC patients; (ii) no influence of therapy on the otherwise intact LPS-induced interleukin-1 productionin vitro; (iii) in some patients a transient corrective influence on the high pretherapeutic immunoglobulin secretion of B cells and their nonresponsiveness to pokeweed mitogen; (iv) low T-cell responses to soluble antigens and alloantigens, which were partially restored during rIL-2 treatment in ARC patients and in one AIDS patient; (v) defective NK activity in PBMC of two AIDS patients, which was found to be restored when measured at the end of rIL-2 therapy; and (vi) a rather constant phenotypic pattern of PBMC in each patient during therapy except for the decreasing proportion of OKT9-positive lymphocytes in AIDS patients, the increasing proportion of Leu8−Leu3a+ lymphocytes in all patients, and in particular, the transient significant decrease in the Leu7+/OKT3+ ratio, which pretherapeutically was very high in AIDS patients (0.78±0.21) and high in ARC patients (0.48±0.06) as compared to healthy controls (0.18±0.08).
Type of Medium: